Risk reducing salpingo-oophorectomy RRSO in BRCA1/2 mutation carriers.

Risk reducing salpingo-oophorectomy RRSO in BRCA1/2 mutation carriers. - Risk reducing salpingo-oophorectomy RRSO in BRCA1/2 mutation carriers.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000027999

Enrollment

Registered

2017-09-01

Start date

2017-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hereditary Breast and Ovarian Cancer

Interventions

Risk reducing salpingo-oophorectomy (RRSO)

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Having a deleterious mutation of BRCA1/2 germline gene

Exclusion criteria

Exclusion criteria: Female has active invasive cancer. Female with mental disabilities and who has difficulty to make a determination of therapy. Female during pregnancy and lactation. Femele with active infectional disease. Female who a doctor consider inappropriate Female under 20 years old

Design outcomes

Primary

Measure	Time frame
The main outcome measure is the complication rate at 4 to 6 days and at 5 weeks after surgery, as indicator of safety of the surgical procedure.	—

Secondary

Measure	Time frame
Secondary outcomes are to evaluate the appearance of menopausal symptoms rate before the surgery and at 6 and 24 months after the surgery	—

Countries

Japan

Contacts

Public ContactUtsumi Fumi

Nagoya university faculty of Medicine Department of Obstetrics and Gynecology

fufumifu@med.nagoya-u.ac.jp052-744-2261

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026